专注于开发和商业化中枢神经系统 (CNS)疾病新型疗法的生物制药公司Axsome Therapeutics (AXSM.US)周三宣布，美国食品药品监督管理局 (FDA)已对其提交的、旨在扩大其抑郁症疗法AXS-05 ...
纽约 - Axsome Therapeutics, Inc. (NASDAQ:AXSM) 今日宣布，该公司已收到美国食品药品监督管理局 (FDA)的正式新药申请 (NDA)前会议纪要，支持其提交发作性睡病治疗药物AXS-12的新药申请。根据 InvestingPro 数据，该公司股票目前交易价格为$148.79，年初至今已取得75.85%的可观回报，并且接近其52周高点$158.56。
Investing.com - Truist证券在 Axsome Therapeutics (NASDAQ:AXSM) 宣布其用于阿尔茨海默病激动症 (ADA)的AXS-05补充新药申请 (sNDA)获FDA优先审查受理后，重申了对该公司的买入评级和200.00美元的目标价。这一目标价较当前148.79美元的价格有34%的上涨空间，与分析师普遍看好该股的共识一致。根据 InvestingPro ...
AXS trades above key SMAs as its specialty lines strategy drives gains, but muted earnings outlook tempers the case.
US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome ...
Zacks Investment Research on MSN
AXSM up on FDA priority review to AXS-05 sNDA in Alzheimer's agitation
Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental ...
Axie Infinity (AXS) has dropped by roughly 90% after peaking out at $172 in November 2021. AXS’s sharp correction has made it one of the worst-performing digital assets among the top-ranking ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈